Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Asks CHMP To Modify European Galvus Label To Recommend Lower Dose

This article was originally published in The Pink Sheet Daily

Executive Summary

Patients taking 50 mg dose of DPP-4 inhibitor had fewer liver enzyme elevations than those taking 100 mg, a profile Novartis wants to include in the label prior to EU launch.

You may also be interested in...



Novartis To Launch Galvus In EU With Lower Dosing Recommendation

EU approves DPP-4 inhibitor with label recommending 50 mg once or twice daily depending on type of combination therapy prescribed.

Novartis To Launch Galvus In EU With Lower Dosing Recommendation

EU approves DPP-4 inhibitor with label recommending 50 mg once or twice daily depending on type of combination therapy prescribed.

Galvus Won’t Proceed In U.S. Without More FDA Clarity On Prospects, Novartis Says

DPP-4 inhibitor’s NDA is on hold in U.S. while firm pursues European launch; Novartis balks at FDA request for large safety study.

Related Content

Topics

UsernamePublicRestriction

Register

PS065458

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel